Key Takeaways The FDA accepted a priority review for Opdivo with AVD in untreated Stage III/IV classical Hodgkin lymphomaThe sBLA is backed by phase III SWOG S1826 data evaluating Opdivo plus AVD in these patients.Opdivo sales rose 7% in Q3 to $2.5B, supported by demand, new launches and global label expansions.Bristol Myers (BMY) has a broad oncology portfolio, which includes blockbuster immuno-oncology drugs, Opdivo, Opdivo Qvantig and Yervoy, among others.Among these, Opdivo (nivolumab) is the top revenu ...